{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'Note: Women of childbearing potential should use a highly effective', 'method of contraception (i.e., pregnancy rate of less than 1% per', 'year) during the trial and for 90 days after the last administration of', 'the IMP. They must be on a stable regimen, for at least 1 month, of', 'combined estrogen and progestogen hormonal contraception with', 'inhibition of ovulation, progestogen-only hormonal contraception', 'associated with inhibition of ovulation, intrauterine device (IUD),', 'intrauterine hormone-releasing system, bilateral tubal occlusion,', 'vasectomized partner, or agree upon continuous abstinence from', 'heterosexual sexual contact.', '2.', 'Male patients who are sexually active and do not intend to use', 'effective methods of contraception (as mentioned above) during the', 'trial or within 90 days after the last dosing or male patients who plan', 'to donate sperm during the trial or within 90 days after the last', 'dosing.', 'Note: Sterilized male patients who have had vasectomy with', 'documented aspermia post-procedure, or male patients who have a', 'partner of non-childbearing potential, can be included.', '3. MGFA Class I and V patients.', '4. Patients with worsening muscle weakness secondary to concurrent', 'infections or medications (aminoglycosides, fluoroquinolones, beta-', 'blockers, etc.).', '5.', 'Patients with known seropositivity or who test positive for an active', 'viral infection at Screening with:', 'Hepatitis B Virus (HBV) (except patients who are seropositive', 'because of HBV vaccination)', 'Hepatitis C Virus (HCV)', 'Human Immunodeficiency Virus (HIV)', '6.', 'Patients with any known severe bacterial, viral or fungal infection or', 'any major episode of infection that required hospitalization or', 'injectable antimicrobial therapy in the last 8 weeks prior to', 'Screening.', '7.', 'Patients with known autoimmune disease other than MG (for', 'example autoimmune thyroiditis, rheumatoid arthritis, ) that would', 'interfere with an accurate assessment of clinical symptoms.', '8. Patients with total IgG level < 6 g/L at Screening.', '9. Patients with documentation of a lack of clinical response to PLEX.', '10. Use of investigational drug within 3 months or 5 half-lives of the', 'drug (whichever is longer) prior to Screening.', '11. Immunoglobulins given by IV (IVIg), subcutaneous or intramuscular', 'route, or PLEX, each within 1 month prior to Screening.', '12. Patients who have a history of malignancy, including malignant', 'thymoma, or myeloproliferative or lymphoproliferative disorders,', 'unless deemed cured by adequate treatment with no evidence of', 'recurrence for > 3 years before Screening. Patients with completely', 'excised non-melanoma skin cancer (such as basal cell carcinoma or', 'argenx BVBA', 'Confidential', 'Page 23 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'squamous cell carcinoma) or cervical carcinoma in situ would be', 'permitted at any time.', '13. Thymectomy when performed <3 months prior to Screening or', 'planned to be performed during the trial period.', '14. Patients with clinical evidence of other significant serious disease or', 'patients who underwent a recent major surgery, which could', 'confound the results of the trial or put the patient at undue risk.', 'Patients with renal/hepatic function impairment can be included.', '15. Patients who previously participated in a clinical trial with', 'ARGX-113.', '16. Patients who received a vaccination (e.g., influenza vaccine) within', 'the last 4 weeks prior to Screening.', '17. Use of any monoclonal antibody, such as rituximab and eculizumab,', 'within 6 months prior to first dosing.', 'Test Product, Dose and Mode', 'In this trial, the test product is ARGX-113, which is a human anti-', 'of Administration:', 'neonatal Fc receptor IgG1 Fc fragment. At Visits 1, 2, 3 and 4 of each', 'Treatment Cycle, a dose of 10 mg/kg of body weight of ARGX-113 will', 'be administered as an intravenous (IV) infusion over a period of 1 hour.', 'The total dose per IMP infusion is capped at 1200 mg for patients with', 'body weight > 120 kg.', 'Placebo, Dose, and Mode of', 'Matching placebo with same buffer components as the test product, but', 'Administration:', 'without the active substance will be administered as an IV infusion over a', 'period of 1 hour at Visits 1, 2, 3 and 4 of each Treatment Cycle.', 'Criteria for Evaluation:', 'Primary Endpoint:', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least 2 points on the total', 'MG-ADL score (compared to TC1B) for at least 4 consecutive weeks with the first of these decreases', 'occurring at the latest 1 week after the last infusion of the IMP in the active versus placebo group in', 'AChR-Ab seropositive patients.', 'Secondary Endpoints:', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least 3 points on the total', 'QMG score (compared to TC1B) for at least 4 consecutive weeks with the first of these decreases', 'occurring at the latest 1 week after the last infusion of the IMP in the active versus placebo group in', 'AChR-Ab seropositive patients.', 'Percentage of patients who, after the first Treatment Cycle, have a decrease of at least 2 points on the total', 'MG-ADL score (compared to TC1B) for at least 4 consecutive weeks with the first of these decreases', 'occurring at the latest 1 week after the last infusion of the IMP in the active versus placebo group in the', 'overall population (AChR-AL seropositive and AChR-Ab seronegative patients).', 'Percentage of time that patients have a \"clinically meaningful improvement\" in total MG-ADL score', 'compared to SEB during the trial (up to and including Day 126) in the active versus placebo group in', 'AChR-Ab seropositive patients.', 'Time from TC1V5 to qualification for re-treatment, as assessed by monitoring the total MG-ADL score', '(compared to TC1B), in the active versus placebo group in the AChR-Ab seropositive patients.', 'Percentage of patients who, after the first Treatment Cycle, show a decrease of at least 2 points on the', 'total MG-ADL score (compared to TC1B) for at least 4 consecutive weeks with the first of these decreases', 'occurring at the latest after 1 or maximum 2 infusions of the IMP in the active versus the placebo group in', 'AChR-Ab seropositive patients.', 'argenx BVBA', 'Confidential', 'Page 24 of 110']\n\n###\n\n", "completion": "END"}